36 completed, 6 terminated, 3 recruiting, 3 unknown. 50 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 50 | Completed 36, Terminated 6, Recruiting 3, Unknown 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Safety and Potency of a High Cabergoline Dosage in Microprolactinomas Cabergoline - Prolactinoma, Prolactin Excess | Phase 3 | Recruiting | University of Sao Paulo General Hospital | 70 | 2026-03-04 | 2026-03-13 |
| A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Debio 4126, Placebo - Acromegaly | Phase 3 | Recruiting | Debiopharm International SA | 119 | 2025-11-26 | 2026-10-23 |
| A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets Cabergoline tablets, Bromocriptine mesylate tablets - Hyperprolactinemia | Phase 3 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 382 | 2025-09-12 | 2025-10-02 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 111 | 2021-12-17 | 2026-07-15 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 58 | 2021-05-12 | 2026-07-15 |
| Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Pegvisomant - Pituitary Disease | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 12 | 2019-10-21 | 2025-11-06 |
| A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot) - Acromegaly | Phase 3 | Completed | Camurus AB | 135 | 2019-10-10 | 2025-12-22 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot), Matching placebo - Acromegaly | Phase 3 | Completed | Camurus AB | 72 | 2019-08-19 | 2026-08-20 |
| Open-label Treatment in Cushing's Syndrome Levoketoconazole - Cushing Syndrome, Cushing Disease | Phase 3 | Completed | Cortendo AB | 51 | 2019-01-07 | 2025-06-19 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma | Phase 3 | Unknown | Samsung Medical Center | 90 | 2018-03-01 | 2018-03-01 |
| Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly octreotide capsules, Matching placebo - Acromegaly | Phase 3 | Unknown | Chiasma, Inc. | 56 | 2017-09-01 | 2020-11-23 |
| Strict IGF-1 Control in Acromegaly Pegvisomant - Acromegaly | Phase 3 | Completed | Unity Health Toronto | 10 | 2017-07-27 | 2021-11-22 |
| Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease osilodrostat, osilodrostat Placebo - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 73 | 2016-10-03 | 2021-11-01 |
| Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Octreotide capsules - Acromegaly | Phase 3 | Completed | Chiasma, Inc. | 146 | 2016-02-01 | 2022-04-22 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Pasireotide LAR - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 123 | 2015-03-31 | 2019-12-10 |
| Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Gallium-68 DOTATOC PET - Pituitary Tumours | Phase 3 | Terminated | Göteborg University | 22 | 2015-01-01 | 2022-03-31 |
| Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Lanreotide Autogel®, Lanreotide Acetate - Acromegaly | Phase 3 | Completed | Ipsen | 128 | 2014-10-01 | 2019-01-29 |
| Treatment for Endogenous Cushing's Syndrome Levoketoconazole - Endogenous Cushing's Syndrome | Phase 3 | Completed | Cortendo AB | 94 | 2014-08-01 | 2021-04-19 |
Showing 20 of 50. Sign in to see all of them.
Acromegaly (33) · Pituitary ACTH Hypersecretion (13) · Pituitary Diseases (8) · Cushing Syndrome (6) · Pituitary Neoplasms (6) · ACTH Syndrome, Ectopic (4) · Hyperprolactinemia (4) · Gigantism (3) · Adenoma (2) · Adrenal Cortex Neoplasms (2) · Choristoma (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Hirsutism (2) · ACTH-Secreting Pituitary Adenoma (1) · Diabetes Mellitus, Type 2 (1)
Brain Diseases (50) · Central Nervous System Diseases (50) · Endocrine System Diseases (50) · Hypothalamic Diseases (50) · Nervous System Diseases (50) · Pituitary Diseases (42) · Bone Diseases (34) · Bone Diseases, Endocrine (34) · Musculoskeletal Diseases (34) · Neoplasms (13) · Endocrine Gland Neoplasms (10) · Neoplasms by Site (10) · Adrenal Gland Diseases (6) · Adrenocortical Hyperfunction (6)
Octreotide (8) · lanreotide (8) · pasireotide (5) · pegvisomant (5) · Mifepristone (4) · Cabergoline (3) · Corlux (3) · Bromocriptine (2) · Duration of Therapy (2) · Calcium (1) · Injections (1) · Osilodrostat (1) · Proton Therapy (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1)
Novartis Pharmaceuticals (9) · Ipsen (8) · Corcept Therapeutics (5) · Ambrilia Biopharma, Inc. (3) · Chiasma, Inc. (3) · Camurus AB (2) · Cortendo AB (2) · Crinetics Pharmaceuticals Inc. (2) · Endo USA Inc., a Keenova Therapeutics Company (2) · Chadi A. Calarge (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Debiopharm International SA (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Göteborg University (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1)
United States (29) · Germany (20) · Italy (20) · Poland (17) · Hungary (16) · Spain (16) · France (15) · United Kingdom (15) · Brazil (11) · Israel (11) · Romania (11) · Turkey (Türkiye) (11) · Belgium (10) · Netherlands (10) · Russia (10)
Raphael Naudin, M.D. (3) · Andreas Moraitis, MD (1) · Chadi Calarge, M.D. (1) · Coleman Gross (1) · Coleman Gross, M.D. (1) · Coleman Gross, MD (1) · Constance Chik, MD (1) · Diego Ferone, M.D (1) · Fredric Cohen, MD (1) · Fredric J Cohen, MD (1)
PMID 25013998, PMID 26507877, PMID 34173129, PMID 40418492, PMID 18248639, PMID 19542735, PMID 19639415, PMID 19898989, PMID 21086246, PMID 21148630, PMID 21212103, PMID 22397653, PMID 22466348, PMID 23746264, PMID 23969184, PMID 23970725, PMID 24287689, PMID 24423301, PMID 25103549, PMID 25260838, PMID 25537481, PMID 25664604, PMID 26437217, PMID 26603536, PMID 27039081, PMID 27405306, PMID 28289402, PMID 29032078, PMID 29112461, PMID 31379734, PMID 31465533, PMID 31542384, PMID 31804965, PMID 31875276, PMID 32117045, PMID 32217809, PMID 32366244, PMID 32385851, PMID 32882036, PMID 33216275, PMID 33897615, PMID 34953531, PMID 35058882, PMID 35325149, PMID 39378125, PMID 39610378, PMID 41052284, PMID 41730814
2019 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), K23MH085005 (1)